Stahl’s Illustrated Index

ADD-H: Comprehensive Teacher’s Rating Scale (ACTeRs), 42
adenosine triphosphate (ATP), 35
ADHD Rating Scale, 42, 119
ADHD Symptom checklist-4 (ADHD-SC4), 42
adolescents: and comorbidity of substance use disorders with ADHD, 54; and development of executive function, 38; differences between diagnosis and treatment of ADHD in adults and, 58; screening and rating scales for ADHD in, 42. See also age; children
Adult Rating Scale, 43
adults: comorbidities and ADHD in, 48, 54; differences between diagnosis and treatment of ADHD in children and, 58; and evolution of ADHD symptoms with age, 41; motor hyperactivity in, 13; persistence of ADHD into, 40; and psychosocial therapies for ADHD in, 115; screening and rating scales for ADHD in, 43; and sleep problems in ADHD patients, 53; and use of ADHD medications by agent and formulation, 59. See also age
Adults ADHD Self-Report Scale (ASRS-v1.1), 43, 128
age: and choice of treatment for ADHD, 65; evolution of ADHD symptoms with, 37–43. See also adolescents; adults; children
alpha 2A agonist, 112
alpha2A receptor, 22, 24, 26–27, 107–108
alpha2A receptor (ADRA 2A) gene, 31
alternative experimental treatments, for ADHD, 114
amphetamine: brand and generic names of, 60; difference between methylphenidate and, 69; formulations of, 77–78; frequency of use in pediatric and adult ADHD patients, 59; mechanism of action of, 70. See also D-amphetamine; D,L-amphetamine
animal models, of iron deficiency, 34
anterior cingulate cortex (ACC), 4–5, 11, 14
anxiety disorders, 29–30, 47–48
arousal: and deficient NE/DA networks, 18–19; excessive mechanisms of, 20–21; and stress, 21; and treatment of ADHD, 61, 63
atomoxetine: and arousal levels in prefrontal cortex, 63; formulations of, 94; frequency of use by pediatric and adult ADHD patients, 59; molecular actions of, 95; pharmacological properties of, 100–101; regional effects of, 96; and weak prefrontal NE and DA signals, 98
attention, and malfunctioning CSTC loops, 5. See also inattention; selective attention; sustained attention

Attention Deficit Disorders Evaluation Scale (ADDES-3), 42

attention deficit hyperactivity disorder (ADHD): alternative theories on etiology of, 32–36; evolution of symptoms with age, 37–43; impact of genetics in, 31, 33; neurobiology and hypothetical pathophysiology of, 1–15; and neurotransmitters, 9, 16–30. See also comorbidity; diagnosis; medications; screening and rating scales; symptoms; treatment

Attention Deficit/Hyperactivity Disorder Test (ADHDT), 42

Attention-Deficit Scales for Adults (ADSA), 43

autism, 47, 114

behavioral inhibition, 33

bipolar disorder, 29, 47–48

brain, and important areas in executive function and motor control, 3. See also neurobiology; neurotransmitters; prefrontal cortex

brain-derived neurotrophic factor (BDNF), 52

brand names, of ADHD medications, 60

Brown Attention-Deficit Disorder Scales for Adults (BADDS), 43

Brown Attention-Deficit Disorder Scales for Children, 42

bupropion: formulations of, 94; molecular actions of, 95; pharmacological properties of, 102–103; regional effects of, 97

“burn-out,” and stimulant abuse, 72

Childhood/Current ADHD Symptom Scale, 43

children: and comorbidities in ADHD, 47; differences between diagnosis and treatment of ADHD in adults and, 58; and evolution of ADHD symptoms with age, 41; and impact of development on ADHD, 39; motor hyperactivity in, 13; screening and rating scales for ADHD in, 42; and sleep problems in ADHD patients, 53; synaptogenesis in prefrontal cortex and sustained attention in, 38; use of ADHD medications by agent and formulation, 59. See also adolescents; age

clonidine: formulations of, 106; mechanisms of action, 107; and obesity, 51; pharmacological properties of, 108–109

cognitive function: and deficient arousal networks, 18; definition of normal, 15; and excessive arousal networks, 20; and maladaptive signal-to-noise ratios, 22–27. See also executive function

College ADHD Response Evaluation (CARE), 43

comorbidity, of ADHD: in adults, 48; in children, 47; and excessive arousal, 21; increase in rates of with age, 39; neurobiology and, 46; and obesity, 49–52; prefrontal cortex and symptoms in, 29; and sleep problems, 30, 47, 53; and substance use disorders, 48, 54; treatment of, 21, 29, 55. See also psychiatric syndromes

compulsivity, and malfunctioning CSTC loops, 5

cognition, and overlap of symptoms among psychiatric syndromes, 8

conduct disorder (CD), 29, 47

Conner’s Adult Attention Deficit/Hyperactivity Disorder Rating Scale (CAARS), 43

Conner’s Parent Rating Scale (CPRS), 42

controlled-release formulations, of stimulants, 78–81

Copeland Symptom Checklist for Attention Deficit Disorder, 42–43

cortical-striatal-thalamic-cortical (CSTC) loops, 3–5, 7

cyclic adenosine monophosphate (cAMP), 23–24

d-amphetamine, 86–87. See also lisdexamfetamine
dendritic spine, and signal distribution, 23 depression, 48. See also major depressive disorder development, impact of on ADHD, 39 dexmethylphenidate, 59 dextroamphetamine, 59 diagnosis, of ADHD: in children/adolescents versus adults, 58; and diagnostic symptoms in DSM-IV, 2; and misdiagnosis of ADHD in sleep problem cases, 53 Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV), 2 diet, and hypotheses on etiology of ADHD, 36 D4 receptor (DRD 4) and D5 receptor (DRD 5) genes, 31 D,L-amphetamine, 88–89 D,L-methylphenidate, 84–85 D-methylphenidate, 82–83 dopamine (DA): and atomoxetine, 98–99; and baseline neuronal firing, 16; bupropion and levels of, 97; and chronic stress, 64; and deficient arousal networks, 18–19; D1 receptors and signal-to-noise ratio, 25–27, 62; and excessive arousal mechanisms, 20; and phasic neuronal firing in reward centers, 17; regulation of transport and availability of synaptic, 67; stimulants and amplification of tonic NE and DA signals, 74 dopamine transporter (DAT) gene, 31 dorsolateral prefrontal cortex (DLPFC): and N-back test, 7; and regulation of executive function, 5, 9; sustained attention and malfunctions of, 4, 7, 28. See also prefrontal cortex dosing: and atomoxetine, 101; and bupropion, 103; and clonidine, 109; and D-amphetamine, 87; and D,L-amphetamine, 89; and D-methylphenidate, 83; and D,L-methylphenidate, 85; and guanfacine, 111; and lisdexamfetamine, 91; and modafinil, 105 drug interactions: and atomoxetine, 101; and bupropion, 103; and clonidine, 109; and D-amphetamine, 87; and D,L-amphetamine, 89; and D-methylphenidate, 83; and D,L-methylphenidate, 85; and guanfacine, 111; and lisdexamfetamine, 91; and modafinil, 105 emotions, and CSTC loops, 5 environmental oversampling syndrome, 49 epilepsy, 47 excessive daytime sleepiness (EDS), 52 executive function: areas of brain important in, 3; and CSTC loops, 5; and N-back test, 6; synaptogenesis in prefrontal cortex and development of, 38. See also attention; cognitive function extended-release formulations, of stimulants, 77, 82 fatty acid desaturase 2 (FADS 2), 31 5HT transporter (5HTTLPR) gene, 31 foods and food additives, and etiology of ADHD, 36 generalized anxiety disorder (GAD), 30 generic names, of ADHD medications, 60 genetics, impact of in ADHD, 31, 33 regulation of synaptic DA, 67; stimulants and amplification of tonic NE and DA signals, 74.
guanfacine: and arousal levels in prefrontal cortex, 63; formulations of, 106; mechanism of action, 107; pharmacological properties of, 110–11

hippocampus, 50

histamine (HA), 9

hyperactivity: and clusters of symptoms, 2; evolution of with age, 41; and prefrontal cortex, 28. See also motor hyperactivity

hyperarousal, 20

hyperpolarization-activated cyclic nucleotide-gated cation channels (HCN channels), 23–25

hypertension, and clonidine, 108

hypooarousal, 52

hypothalamic-pituitary-adrenal axis, 99

IL-8 (cytokine), 50

immediate-release formulations, of stimulants, 76–77

impairment: clusters of symptoms and degree of in ADHD, 2; and treatment of comorbid disorders in ADHD, 55

impulsivity: and clusters of symptoms, 2; and eating habits, 49; evolution of with age, 41; and malfunctioning CSTC loops, 5; and orbital frontal cortex, 12, 28

inattention: and clusters of symptoms, 2; evolution of with age, 41; as symptom in different psychiatric disorders, 30. See also attention

individualized treatment plan, 55

information processing, and CSTC loop, 11. See also executive function

iron deficiency hypothesis, 34, 47

lacatate, 35

learning disabilities, 47

lisdexamfetamine: and amplification of tonic NE/DA signals, 74; formulations of, 77, 81; pharmacological properties of, 90–91

locus coeruleus (LC), 3, 26–27

long-term potentiation (LTP), 50

magnesium, 114

major depressive disorder (MDD), 8, 30, 102. See also depression

mazindol, 52

medical illness. See comorbidity

medications: brand and generic names of, 60; crossover effects of in obesity and ADHD, 51; frequency of use by agent and formulation for children and adults, 59. See also dosing; drug interactions; non-stimulant drugs; side effects; stimulants

metformin, 51

methamphetamine, 59

methylphenidate: brand and generic names of, 60; difference between amphetamine and, 69; formulations of, 74, 76, 79–80; frequency of use in pediatric and adult ADHD patients, 59; mechanism of action of, 68; and obesity, 51. See also D-methylphenidate

modafinil, 94, 104

mood disorders, and comorbidity with ADHD, 29. See also depression

motor control, 3, 5

motor hyperactivity, and prefrontal motor cortex, 13. See also hyperactivity

multiple bead system, for controlled-release formulations, 78

narcolepsy, 8, 30

nature vs. nurture theory, 33

N-back test, 6–7

neurobiology: and comorbidities with ADHD, 46; and hypothetical pathophysiology of ADHD, 1–15. See also brain; neurotransmitters

neuronal and glial energetics hypothesis, 35

neurotransmitters: and links between obesity and ADHD, 50; role of in hypothetical pathophysiology of ADHD, 9, 16–30. See also dopamine (DA); neurobiology; norepinephrine (NE)

nicotine addiction, 102

non-stimulant drugs: and alpha 2A agonists, 112; and alternative experimental treatments, 114; brand and generic names of, 60; formulations of,
94, 106; overview of, 93; and treatment of oppositional symptoms, 113. See also atomoxetine; bupropion; clonidine; guanfacine; modafinil.

norepinephrine (NE): alpha2A receptors and signal-to-noise ratio, 24, 26–27, 62; and atomoxetine, 98–99; and baseline neuronal firing, 16; and chronic stress, 64; and deficient arousal networks, 18–19; and excessive arousal mechanisms, 20; stimulants and amplification of tonic and phasic NE/DA signals, 74–75; stimulants and synaptic levels of, 69. See also norepinephrine transporter (NET); neurotransmitters.

norepinephrine transporter (NET), 95

norepinephrine reuptake inhibitor, 100, 102

norepinephrine transporter (NET), 68, 74, 96, 99

nucleus accumbens (NAcc), 5, 17

nutritional deficiencies, in autism and ADHD, 114. See also diet.

O-back variant, of N-back test, 6

obesity, comorbidity of with ADHD, 49–52

obstructive sleep apnea, 30

omega-3-fatty acids, 114

1-back variant, of N-back test, 6

oppositional defiant disorder (ODD), 29, 47

oppositional symptoms, treatment of ADHD and, 113

orbital frontal cortex (OFC): and core symptoms of ADHD, 28; impulsive symptoms and impairments of, 4–5, 12; interconnected networks in ADHD and, 14. See also prefrontal cortex.

osmotic controlled-release oral delivery system (OROS), 79

patches, and controlled-release medications, 74, 76, 80

phasic firing, of DA/NE neurons, 17, 20, 72

prefrontal cortex: arousal levels and treatment of ADHD, 61, 63; and cognitive function, 15; and comorbid symptoms, 29; core symptoms of ADHD and malfunction of, 4, 28; and interconnected networks in ADHD, 14; and motor hyperactivity, 13; and role of DA and NE in signal-to-noise ratio, 26–27, 62; synaptogenesis in and development of executive function, 38. See also dorsolateral prefrontal cortex; orbital frontal cortex.

prevalence: of ADHD in children and adolescents versus adults, 58; of sleep problems in children with ADHD, 53

primary disorder, and comorbidity of ADHD with substance use disorders, 54

problem-solving, assessment of with N-back test, 7

prodrug, 81

psychiatric syndromes, overlap of symptoms among, 8. See also anxiety disorders; comorbidity; conduct disorder; mood disorders; oppositional defiant disorder.

psychosocial therapies, for ADHD, 115

pulsatile firing, 71

rating scales. See screening and rating scales.

restless leg syndrome, 34, 47

reward conditioning, and DA pathways in nucleus accumbens, 17

risk factors, for behavioral inhibition, 33

screening and rating scales, 42–43, 119–29

selective attention: and prefrontal cortex, 28; and Stroop task, 10–11. See also attention.

selective norepinephrine reuptake inhibitor (NRI), 95

selective serotonin reuptake inhibitor (SSRI), 68

serotonin 1B receptor (HTR 1B) gene, 31

shift work sleep disorder, 30

side effects: of atomoxetine, 101; of bupropion, 103; of clonidine, 109; of D-amphetamine, 87; of D,L-amphetamine, 89; of...
side effects (cont.)
D-methylphenidate, 83; of
D,L-methylphenidate, 85; of guanfacine, 111; of lisdexamfetamine, 91; of
modafinil, 105
signal-to-noise ratios, and cognitive
function, 22–27
sleep deprivation, 30
sleep problems, comorbidity of with ADHD, 30, 47, 53
SNAP-IV Rating Scale – Revised
(SNAP-IV-R), 42, 121–25
SODAS microbeads d-methylphenidate, 76
spansules, 78
stimulants: and amplification of tonic and
phasic NE and DA signals, 74–75; and
controlled-release formulations, 78–81; paradoxical effect of in ADHD patients,
73; pulsatile versus slow/sustained drug
delivery and, 71; and regulation of
synaptic DA, 67; and sleep problems,
53; and substance abuse, 72, 75. See
also amphetamine; dexamethylphenidate;
dextroamphetamine; lisdexamfetamine;
methamphetamine; methylphenidate
stress: and atomoxetine, 99; and excessive
arousal, 21; and treatment of ADHD, 64
Stroop task, 10–11
substance abuse: comorbidity of substance
use disorders with ADHD, 48, 54; and
stimulants, 72, 75, 86
subsyndromal symptoms, and persistence
of ADHD into adulthood, 40
sustained attention: and N-back test, 6–7;
and prefrontal cortex, 28, 38. See also
attention
sustained-release formulations, of
stimulants, 76–77, 84
SWAN Rating Scale for ADHD, 42,
126–27
symptoms, of ADHD: different disorders
and similar, 30; and DSM-IV, 2; evolution
of with patient age, 37–43; non-stimulant
drugs and oppositional, 113; and
overlaps among psychiatric syndromes,
8; and prefrontal cortex, 4, 28–29. See
also attention; hyperactivity; impulsivity
synaptic protein (SNAP 25) gene, 31
synaptic pruning, 38
television programs, 49
Test of Everyday Attention for Children
(TEA-Ch), 42
Test of Variables of Attention, 43
time-release beads racemic
methylphenidate, 76
tonic firing, of DA and NE systems, 16–20,
72, 74
Tourette’s syndrome, 34, 47
transdermal methylphenidate patch, 74,
84, 86
treatment, of ADHD: age of patient and
choice of, 65; alternative experimental
forms of, 114; and arousal levels in
prefrontal cortex, 61, 63; of
comorbidities, 21, 29, 55; and
differences between
children/adolescents versus adults, 58;
overview of issues in, 57–65; for similar
symptoms in different psychiatric
disorders, 30; and stress, 64. See also
medications
TrkB receptor agonists, 52
tuberomammillary nucleus (TMN), 9
two-bead system, for controlled-release
formulations, 78
Vanderbilt ADHD Diagnostic Rating Scales,
42
ventral tegmental area (VTA), 3, 26–27
vesicular monoamine transporter (VMAT),
67, 70
vitamin B6, 114
Wender Utah Rating Scale (WURS), 43,
120
Werry-Weiss-Peters Activity Rating Scale,
42
withdrawal, and stimulant abuse, 72
zinc, 114